Investigations of survivin: The past, present and future

Frontiers in Bioscience

Volumn 16, Issue 3, 2011, Pages 952-961

  Cheung, Chun Hei Antonio ^a   Cheng, Li Ting ^b   Chang, Kwang Yu ^a   Chen, Huang Hui ^a   Chang, Jang Yang ^a,c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

BIRC5; Cancer; Hsp90; IAPs; Review; Survivin; YM155

Indexed keywords

INTRACISTERNAL A-PARTICLES;

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; BIRC5 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; NAPHTHOQUINONE; SMALL INTERFERING RNA;

BIOSYNTHESIS; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; NEOPLASM; REVIEW;

CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NAPHTHOQUINONES; NEOPLASMS; RNA, SMALL INTERFERING;

EID: 79955025768     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3728     Document Type: Article

References (92)

1. K. W. Sung, J. Choi, Y. K. Hwang, S. J. Lee, H. J. Kim, S. H. Lee, K. H. Yoo, H. L. Jung and H. H. Koo: Overexpression of Apollon, an antiapoptotic protein, is associated with poor prognosis in childhood de novo acute myeloid leukemia. Clin Cancer Res, 13(17), 5109-14 (2007) (Pubitemid 47502078)
2. S. Qi, S. Mogi, H. Tsuda, Y. Tanaka, K. Kozaki, I. Imoto, J. Inazawa, S. Hasegawa and K. Omura: Expression of cIAP-1 correlates with nodal metastasis in squamous cell carcinoma of the tongue. Int J Oral Maxillofac Surg, 37(11), 1047-53 (2008)
3. J. W. Tichelaar, Y. Zhang, J. C. leRiche, P. W. Biddinger, S. Lam and M. W. Anderson: Increased staining for phospho-Akt, p65/RELA and cIAP-2 in pre-neoplastic human bronchial biopsies. BMC Cancer, 5, 155 (2005)
4. B. W. Richter, S. S. Mir, L. J. Eiben, J. Lewis, S. B. Reffey, A. Frattini, L. Tian, S. Frank, R. J. Youle, D. L. Nelson, L. D. Notarangelo, P. Vezzoni, H. O. Fearnhead and C. S. Duckett: Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Mol Cell Biol, 21(13), 4292-301 (2001) (Pubitemid 32565310)
5. J. G. Chang, Y. J. Jong, S. P. Lin, B. W. Soong, C. H. Tsai, T. Y. Yang, C. P. Chang and W. S. Wang: Molecular analysis of survival motor neuron (SMN) and neuronal apoptosis inhibitory protein (NAIP) genes of spinal muscular atrophy patients and their parents. Hum Genet, 100(5-6), 577-81 (1997)
6. P. Gazzaniga, A. Gradilone, L. Giuliani, O. Gandini, I. Silvestri, I. Nofroni, G. Saccani, L. Frati and A. M. Agliano: Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol, 14(1), 85-90 (2003) (Pubitemid 36150264)
7. D. E. Burstein, M. T. Idrees, G. Li, M. Wu and T. Kalir: Immunohistochemical detection of the X-linked inhibitor of apoptosis protein (XIAP) in cervical squamous intraepithelial neoplasia and squamous carcinoma. Ann Diagn Pathol, 12(2), 85-9 (2008) (Pubitemid 351312907)
8. G. M. Kasof and B. C. Gomes: Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem, 276(5), 3238-46 (2001)
9. W. Wang, H. Luo and A. Wang: Expression of survivin and correlation with PCNA in osteosarcoma. Journal of Surgical Oncology, 93(7), 578-84 (2006) (Pubitemid 43806994)
10. I. Esposito, J. Kleeff, I. Abiatari, X. Shi, N. Giese and P. Schirmacher: cIAP2 Overexpression is an early event in pancreatic cancer progression. Journal of Clinical Pathology (2006)
11. H. Takeuchi, J. Kim, A. Fujimoto, N. Umetani, T. Mori, A. Bilchik, R. Turner, A. Tran, C. Kuo and D. S. Hoon: X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling. Clinical Cancer Research, 11(21), 7621-8 (2005) (Pubitemid 41611602)
12. T. Samuel, K. Okada, M. Hyer, K. Welsh, J. M. Zapata and J. C. Reed: cIAP1 Localizes to the nuclear compartment and modulates the cell cycle. Cancer Research, 65(1), 210-8 (2005) (Pubitemid 40070812)
13. S. Lu, B. Zhang and Z. Wang: Expression of survivin, cyclinD1, p21(WAF1), caspase-3 in cervical cancer and its relation with prognosis. Journal of Huazhong University of Science and Technology. Medical Sciences, 25(1), 78-81 (2005)
14. M. E. Johnson and E. W. Howerth: Survivin: a bifunctional inhibitor of apoptosis protein. Veterinary Pathology, 41(6), 599-607 (2004) (Pubitemid 39573750)
15. M. Delvaeye, A. De Vriese, F. Zwerts, I. Betz, M. Moons, M. Autiero and E. M. Conway: Role of the 2 zebrafish survivin genes in vasculo-angiogenesis, neurogenesis, cardiogenesis and hematopoiesis. BMC Dev Biol, 9, 25 (2009)
16. Y. Jiang, A. de Bruin, H. Caldas, J. Fangusaro, J. Hayes, E. M. Conway, M. L. Robinson and R. A. Altura: Essential role for survivin in early brain development. J Neurosci, 25(30), 6962-70 (2005) (Pubitemid 41077004)
17. C. Y. Lin, H. C. Hung, R. C. Kuo, C. P. Chiang and M. Y. Kuo: Survivin expression predicts poorer prognosis in patients with areca quid chewing-related oral squamous cell carcinoma in Taiwan. Oral Oncol, 41(6), 645-54 (2005) (Pubitemid 40828883)
18. K. F. Hsu, C. K. Lin, C. P. Yu, C. Tzao, S. C. Lee, Y. Y. Lee, W. C. Tsai and J. S. Jin: Cortactin, fascin, and survivin expression associated with clinicopathological parameters in esophageal squamous cell carcinoma. Dis Esophagus, 22(5), 402-8 (2009)
19. S. F. Preuss, A. Weinell, M. Molitor, M. Stenner, R. Semrau, U. Drebber, S. J. Weissenborn, E. J. Speel, C. Wittekindt, O. Guntinas-Lichius, T. K. Hoffmann, G. D. Eslick and J. P. Klussmann: Nuclear survivin expression is associated with HPV-independent carcinogenesis and is an indicator of poor prognosis in oropharyngeal cancer. Br J Cancer, 98(3), 627-32 (2008) (Pubitemid 351214523)
20. X. Gu and H. L. Lin: [Analysis of survivin expression in subtypes of lymphoma]. Ai Zheng, 23(6), 655-61 (2004)
21. A. A. Sahasrabuddhe, R. C. Nayak and C. M. Gupta: Ancient Leishmania coronin (CRN12) is involved in microtubule remodeling during cytokinesis. J Cell Sci, 122(Pt 10), 1691-9 (2009)
22. A. I. Sarela, R. C. Macadam, S. M. Farmery, A. F. Markham and P. J. Guillou: Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut, 46(5), 645-50 (2000) (Pubitemid 30305781)
23. H. Kawasaki, M. Toyoda, H. Shinohara, J. Okuda, I. Watanabe, T. Yamamoto, K. Tanaka, T. Tenjo and N. Tanigawa: Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer, 91(11), 2026-32 (2001) (Pubitemid 32476366)
24. S. Shin, B. J. Sung, Y. S. Cho, H. J. Kim, N. C. Ha, J. I. Hwang, C. W. Chung, Y. K. Jung and B. H. Oh: An antiapoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry, 40(4), 1117-23 (2001) (Pubitemid 32108606)
25. I. Tamm, Y. Wang, E. Sausville, D. A. Scudiero, N. Vigna, T. Oltersdorf and J. C. Reed: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res, 58(23), 5315-20 (1998) (Pubitemid 28551107)
26. T. Dohi, E. Beltrami, N. R. Wall, J. Plescia and D. C. Altieri: Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest, 114(8), 1117-27 (2004) (Pubitemid 39578701)
27. L. Chantalat, D. A. Skoufias, J. P. Kleman, B. Jung, O. Dideberg and R. L. Margolis: Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Mol Cell, 6(1), 183-9 (2000)
28. X. Wang, C. Yang, J. Chai, Y. Shi and D. Xue: Mechanisms of AIF-mediated apoptotic DNA degradation in Caenorhabditis elegans. Science, 298(5598), 1587-92 (2002) (Pubitemid 35387191)
29. C. Cande, I. Cohen, E. Daugas, L. Ravagnan, N. Larochette, N. Zamzami and G. Kroemer: Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria. Biochimie, 84(2-3), 215-22 (2002)
30. C. H. Cheung, H. H. Chen, C. C. Kuo, C. Y. Chang, M. S. Coumar, H. P. Hsieh and J. Y. Chang: Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol Cancer, 8, 43 (2009)
31. M. Okuya, H. Kurosawa, J. Kikuchi, Y. Furukawa, H. Matsui, D. Aki, T. Matsunaga, T. Inukai, H. Goto, R. A. Altura, K. Sugita, O. Arisaka, A. T. Look and T. Inaba: Upregulation of Survivin by the E2A-HLF Chimera Is Indispensable for the Survival of t(17;19)-positive Leukemia Cells. Journal of Biological Chemistry, 285(3), 1850-1860 (2010)
32. D. O. Croci, I. S. Cogno, N. B. Vittar, E. Salvatierra, F. Trajtenberg, O. L. Podhajcer, E. Osinaga, G. A. Rabinovich and V. A. Rivarola: Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway. J Cell Biochem, 105(2), 381-90 (2008)
33. G. Vader, J. J. Kauw, R. H. Medema and S. M. Lens: Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody. EMBO Rep, 7(1), 85-92 (2006)
34. M. A. Bolton, W. Lan, S. E. Powers, M. L. McCleland, J. Kuang and P. T. Stukenberg: Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell, 13(9), 3064-77 (2002) (Pubitemid 35034246)
35. S. P. Wheatley, A. Carvalho, P. Vagnarelli and W. C. Earnshaw: INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis. Curr Biol, 11(11), 886-90 (2001) (Pubitemid 32532816)
36. A. A. Jeyaprakash, U. R. Klein, D. Lindner, J. Ebert, E. A. Nigg and E. Conti: Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell, 131(2), 271-85 (2007) (Pubitemid 47576137)
37. A. G. Uren, L. Wong, M. Pakusch, K. J. Fowler, F. J. Burrows, D. L. Vaux and K. H. Choo: Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Current Biology, 10(21), 1319-28 (2000)
38. J. Rosa, P. Canovas, A. Islam, D. C. Altieri and S. J. Doxsey: Survivin modulates microtubule dynamics and nucleation throughout the cell cycle. Mol Biol Cell, 17(3), 1483-93 (2006) (Pubitemid 43376565)
39. P. Fortugno, N. R. Wall, A. Giodini, D. S. O'Connor, J. Plescia, K. M. Padgett, S. Tognin, P. C. Marchisio and D. C. Altieri: Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci, 115(Pt 3), 575-85 (2002) (Pubitemid 34182984)
40. H. Roca, Z. Varsos and K. J. Pienta: CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin upregulation. J Biol Chem, 283(36), 25057-73 (2008)
41. H. Roca, Z. S. Varsos, K. Mizutani and K. J. Pienta: CCL2, survivin and autophagy: new links with implications in human cancer. Autophagy, 4(7), 969-71 (2008)
42. M. Pennati, M. Folini and N. Zaffaroni: Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis, 28(6), 1133-9 (2007) (Pubitemid 47062670)
43. H. Kojima, M. Iida, Y. Yaguchi, R. Suzuki, N. Hayashi, H. Moriyama and Y. Manome: Enhancement of Cisplatin sensitivity in squamous cell carcinoma of the head and neck transfected with a survivin antisense gene. Arch Otolaryngol Head Neck Surg, 132(6), 682-5 (2006) (Pubitemid 43927048)
44. M. Zhang, N. Mukherjee, R. S. Bermudez, D. E. Latham, M. A. Delaney, A. L. Zietman, W. U. Shipley and A. Chakravarti: Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate, 64(3), 293-302 (2005) (Pubitemid 40980871)
45. T. Nomura, M. Yamasaki, Y. Nomura and H. Mimata: Expression of the inhibitors of apoptosis proteins in cisplatinresistant prostate cancer cells. Oncol Rep, 14(4), 993-7 (2005)
46. M. Ikeguchi, J. Liu and N. Kaibara: Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment. Apoptosis, 7(1), 23-9 (2002) (Pubitemid 34145388)
47. J. H. Xu, A. X. Wang, H. Z. Huang, J. G. Wang, C. B. Pan and B. Zhang: Survivin shRNA induces caspase-3-dependent apoptosis and enhances cisplatin sensitivity in squamous cell carcinoma of the tongue. Oncol Res, 18(8), 377-85 (2010)
48. N. Zaffaroni, M. Pennati, G. Colella, P. Perego, R. Supino, L. Gatti, S. Pilotti, F. Zunino and M. G. Daidone: Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci, 59(8), 1406-12 (2002)
49. S. Q. He, H. Rehman, M. G. Gong, Y. Z. Zhao, Z. Y. Huang, C. H. Li, W. G. Zhang and X. P. Chen: Inhibiting survivin expression enhances TRAIL-induced tumoricidal activity in human hepatocellular carcinoma via cell cycle arrest. Cancer Biol Ther, 6(8), 1247-57 (2007) (Pubitemid 351590379)
50. R. Moriai, N. Tsuji, M. Moriai, D. Kobayashi and N. Watanabe: Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat, 117(2), 261-71 (2009)
51. M. Zhang, D. E. Latham, M. A. Delaney and A. Chakravarti: Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene, 24(15), 2474-82 (2005) (Pubitemid 40593038)
52. F. Liu, Z. H. Xie, G. P. Cai and Y. Y. Jiang: The effect of survivin on multidrug resistance mediated by Pglycoprotein in MCF-7 and its adriamycin resistant cells. Biol Pharm Bull, 30(12), 2279-83 (2007) (Pubitemid 350223727)
53. J. Tran, Z. Master, J. L. Yu, J. Rak, D. J. Dumont and R. S. Kerbel: A role for survivin in chemoresistance of endothelial cells mediated by VEGF Proceedings of the National Academy of Sciences of the United States of America, 99(7), 4349-4354 (2002) (Pubitemid 34285988)
54. D. S. O' Connor, J. S. Schechner, C. Adida, M. Mesri, A. L. Rothermel, F. Li, A. K. Nath, J. S. Pober and D. C. Altieri: Control of Apoptosis during Angiogenesis by Survivin Expression in Endothelial Cells. The American Journal of Pathology, 156(2), 393-398 (2000) (Pubitemid 30643793)
55. D. S. O'Connor, J. S. Schechner, C. Adida, M. Mesri, A. L. Rothermel, F. Li, A. K. Nath, J. S. Pober and D. C. Altieri: Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol, 156(2), 393-8 (2000) (Pubitemid 30643793)
56. G. Jiang, B. Ren, L. Xu, S. Song, C. Zhu and F. Ye: Survivin may enhance DNA double-strand break repair capability by up-regulating Ku70 in human KB cells. Anticancer Res, 29(1), 223-8 (2009)
57. G. Y. Miao, Q. M. Lu and X. L. Zhang: Downregulation of survivin by RNAi inhibits growth of human gastric carcinoma cells. World J Gastroenterol, 13(8), 1170-4 (2007)
58. Y. Wang, H. Zhu, L. Quan, C. Zhou, J. Bai, G. Zhang, Q. Zhan and N. Xu: Downregulation of survivin by RNAi inhibits the growth of esophageal carcinoma cells. Cancer Biol Ther, 4(9), 974-8 (2005) (Pubitemid 41598593)
59. Y. Zhang, Z. D. Chen, C. J. Du, G. Xu and W. Luo: siRNA targeting survivin inhibits growth and induces apoptosis in human renal clear cell carcinoma 786-O cells. Pathol Res Pract, 205(12), 823-7 (2009)
60. S. Ning, S. Fuessel, M. Kotzsch, K. Kraemer, M. Kappler, U. Schmidt, H. Taubert, M. P. Wirth and A. Meye: siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol, 25(4), 1065-71 (2004)
61. Q. X. Li, J. Zhao, J. Y. Liu, L. T. Jia, H. Y. Huang, Y. M. Xu, Y. Zhang, R. Zhang, C. J. Wang, L. B. Yao, S. Y. Chen and A. G. Yang: Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther, 5(7), 860-6 (2006) (Pubitemid 44775148)
62. J. J. Wang, Y. Zheng, F. Yang, P. Zhao and H. F. Li: Survivin small interfering RNA transfected with a microbubble and ultrasound exposure inducing apoptosis in ovarian carcinoma cells. Int J Gynecol Cancer, 20(4), 500-6 (2010)
63. J. B. Hansen, N. Fisker, M. Westergaard, L. S. Kjaerulff, H. F. Hansen, C. A. Thrue, C. Rosenbohm, M. Wissenbach, H. Orum and T. Koch: SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther, 7(9), 2736-45 (2008)
64. T. Liu, B. Brouha and D. Grossman: Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene, 23(1), 39-48 (2004) (Pubitemid 38142238)
65. J. R. Kanwar, W. P. Shen, R. K. Kanwar, R. W. Berg and G. W. Krissansen: Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst, 93(20), 1541-52 (2001) (Pubitemid 32998483)
66. L. Pan, X. C. Peng, F. Leng, Q. Z. Yuan, Y. Shan, D. D. Yu, Z. Y. Li, X. Chen, W. J. Xiao, Y. Wen, T. T. Ma, L. Yang, Y. Q. Mao, H. S. Yang, Y. Q. Wei and C. T. Wang: Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer. J Cancer Res Clin Oncol (2010)
67. D. S. O'Connor, D. Grossman, J. Plescia, F. Li, H. Zhang, A. Villa, S. Tognin, P. C. Marchisio and D. C. Altieri: Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A, 97(24), 13103-7 (2000)
68. C. H. A. Cheung, J. Kanwar and G. W. Krissansen: A cell-permeable dominant-negative Survivin protein as a tool to understand how Survivin maintains tumour cell survival. Ejc Supplements, 4(12), 488 (2006)
69. C. Shen, W. Liu, A. K. Buck and S. N. Reske: Proapoptosis and anti-proliferation effects of a recombinant dominant-negative survivin-T34A in human cancer cells. Anticancer Res, 29(4), 1423-8 (2009)
70. S. Khan, J. R. Aspe, M. G. Asumen, F. Almaguel, O. Odumosu, S. Acevedo-Martinez, M. De Leon, W. H. Langridge and N. R. Wall: Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. Br J Cancer, 100(7), 1073-86 (2009)
71. M. S. Coumar, C. H. Cheung, J. Y. Chang and H. P. Hsieh: Advances in Aurora kinase inhibitor patents. Expert Opin Ther Pat, 19(3), 321-56 (2009)
72. C. H. Cheung, M. S. Coumar, H. P. Hsieh and J. Y. Chang: Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs, 18(4), 379-98 (2009)
73. T. Satoh, I. Okamoto, M. Miyazaki, R. Morinaga, A. Tsuya, Y. Hasegawa, M. Terashima, S. Ueda, M. Fukuoka, Y. Ariyoshi, T. Saito, N. Masuda, H. Watanabe, T. Taguchi, T. Kakihara, Y. Aoyama, Y. Hashimoto and K. Nakagawa: Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res, 15(11), 3872-80 (2009)
74. T. Minematsu, M. Iwai, K. Sugimoto, N. Shirai, T. Nakahara, T. Usui and H. Kamimura: Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3- (pyrazin-2-ylmethyl)-4,9-dihydro-1 H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells. Drug Metab Dispos, 37(3), 619-28 (2009)
75. G. Giaccone, P. Zatloukal, J. Roubec, K. Floor, J. Musil, M. Kuta, R. J. van Klaveren, S. Chaudhary, A. Gunther and S. Shamsili: Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol, 27(27), 4481-6 (2009)
76. A. W. Tolcher, A. Mita, L. D. Lewis, C. R. Garrett, E. Till, A. I. Daud, A. Patnaik, K. Papadopoulos, C. Takimoto, P. Bartels, A. Keating and S. Antonia: Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol, 26(32), 5198-203 (2008)
77. T. Iwasa, I. Okamoto, M. Suzuki, T. Nakahara, K. Yamanaka, E. Hatashita, Y. Yamada, M. Fukuoka, K. Ono and K. Nakagawa: Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res, 14(20), 6496-504 (2008)
78. T. Nakahara, M. Takeuchi, I. Kinoyama, T. Minematsu, K. Shirasuna, A. Matsuhisa, A. Kita, F. Tominaga, K. Yamanaka, M. Kudoh and M. Sasamata: YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res, 67(17), 8014-21 (2007) (Pubitemid 47395135)
79. T. Iwasa, I. Okamoto, K. Takezawa, K. Yamanaka, T. Nakahara, A. Kita, H. Koutoku, M. Sasamata, E. Hatashita, Y. Yamada, K. Kuwata, M. Fukuoka and K. Nakagawa: Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br J Cancer (2010)
80. K. D. Lewis, W. Samlowski, J. Ward, J. Catlett, L. Cranmer, J. Kirkwood, D. Lawson, E. Whitman and R. Gonzalez: A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs (2009)
81. M. D. Siegelin, A. Habel and T. Gaiser: 17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis. Neurobiol Dis, 33(2), 243-9 (2009)
82. J. Okamoto, I. Mikami, Y. Tominaga, K. M. Kuchenbecker, Y. C. Lin, D. T. Bravo, G. Clement, A. Yagui-Beltran, M. R. Ray, K. Koizumi, B. He and D. M. Jablons: Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. J Thorac Oncol, 3(10), 1089-95 (2008)
83. J. Plescia, W. Salz, F. Xia, M. Pennati, N. Zaffaroni, M. G. Daidone, M. Meli, T. Dohi, P. Fortugno, Y. Nefedova, D. I. Gabrilovich, G. Colombo and D. C. Altieri: Rational design of shepherdin, a novel anticancer agent. Cancer Cell, 7(5), 457-68 (2005) (Pubitemid 40719129)
84. P. Fortugno, E. Beltrami, J. Plescia, J. Fontana, D. Pradhan, P. C. Marchisio, W. C. Sessa and D. C. Altieri: Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A, 100(24), 13791-6 (2003)
85. C. H. Cheung, H. H. Chen, L. T. Cheng, K. W. Lyu, J. R. Kanwar and J. Y. Chang: Targeting Hsp90 with small molecule inhibitors induces the over-expression of the antiapoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells. Mol Cancer, 9, 77 (2010)
86. S.-a. Wang and J.-J. Hung: Hsp90 localized with Sp1 in mitosis involves in Sp1 stability. FASEB J., 22(1-MeetingAbstracts), 838.2- (2008)
87. J. Imai, M. Maruya, H. Yashiroda, I. Yahara and K. Tanaka: The molecular chaperone Hsp90 plays a role in the assembly and maintenance of the 26S proteasome. EMBO J, 22(14), 3557-67 (2003) (Pubitemid 36898333)
88. L. Stingl, T. Stuhmer, M. Chatterjee, M. R. Jensen, M. Flentje and C. S. Djuzenova: Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Br J Cancer, 102(11), 1578-91 (2010)
89. R. A. Lopez, A. B. Goodman, M. Rhodes, J. A. Blomberg and J. Heller: The anticancer activity of the transcription inhibitor terameprocol (meso-tetra-O-methyl nordihydroguaiaretic acid) formulated for systemic administration. Anticancer Drugs, 18(8), 933-9 (2007) (Pubitemid 47220712)
90. N. Khanna, R. Dalby, M. Tan, S. Arnold, J. Stern and N. Frazer: Phase I/II clinical safety studies of terameprocol vaginal ointment. Gynecol Oncol, 107(3), 554-62 (2007) (Pubitemid 350160872)
91. P. Karna, S. M. Sharp, C. Yates, S. Prakash and R. Aneja: EM011 activates a survivin-dependent apoptotic program in human non-small cell lung cancer cells. Mol Cancer, 8, 93 (2009)
92. M. A. Jordan and L. Wilson: Microtubules as a target for anticancer drugs. Nat Rev Cancer, 4(4), 253-265 (2004) (Pubitemid 38525281)